Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline

Tarsus Pharmaceuticals announced it has closed its acquisition of iRenix Medical, adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline. The deal is aimed at expanding Tarsus’ eye-care footprint and enabling entry into the retina market, which is modestly supportive for longer-term growth.

Analysis

Tarsus Pharmaceuticals announced it has closed its acquisition of iRenix Medical, adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline. The deal is aimed at expanding Tarsus’ eye-care footprint and enabling entry into the retina market, which is modestly supportive for longer-term growth.